Why Tylenol Maker Kenvue Stock Just Popped

2025 hasn't been kind to Kenvue (NYSE: KVUE) stock lately. Shares of the one-time Johnson & Johnson unit got hit hard after President Donald Trump said it was "not good" for women to take Tylenol (which Kenvue manufactures) during pregnancy, echoing unverified claims that the pain reliever can cause autism in children.The good news for Kenvue is that the bad press didn't prevent the company, which also makes consumable consumer medical products such as Band-Aids, Listerine, and Zyrtec allergy medicine, from beating earnings this morning. Kenvue just reported a $0.28 adjusted profit on sales of $3.8 billion.The better news is that Kenvue won't have to worry about earnings much longer, because Kimberly-Clark (NASDAQ: KMB) is going to buy it.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool